Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04465487 · ClinicalTrials.gov registry record · Phase 1
Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT04465487 is a Phase 1 study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 38 participants.
The verdict
NCT04465487, a Phase 1 study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
There are two main goals of this study: The first is to find the highest safe dose of REGN6569 when given with cemiplimab. The second is to get some initial information about how well the REGN6569 in combination with cemiplimab may help shrink certain types of cancer. The study is also looking at: * Side effects that may be experienced by people taking REGN6569 alone and with cemiplimab * How REGN6569 and cemiplimab work in the body * How much REGN6569 and cemiplimab is in your blood * To see if REGN6569 can lower the number of Treg cells in tumors * To see if REGN6569 and cemiplimab can shrink tumors when given together
Interventions
- DRUG Cemiplimab
- DRUG REGN6569
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2020-10-05 |
| Est. Completion | 2025-02-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04465487
The ClinicalTrials.gov registry entry for NCT04465487 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cemiplimab is the first listed.
NCT04465487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04465487 about?
NCT04465487 is a clinical study titled "Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies". There are two main goals of this study: The first is to find the highest safe dose of REGN6569 when given with cemiplimab. The second is to get some initial information about how well the REGN6569 in combination with cemiplimab may help shrink certain types of cancer. The study is also looking at: ...
What is the current status of trial NCT04465487?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2020-10-05. Estimated completion is 2025-02-07.
What interventions are being tested in trial NCT04465487?
The interventions under investigation include: Cemiplimab (DRUG), REGN6569 (DRUG).
Who is sponsoring clinical trial NCT04465487?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.